[Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)]
- PMID: 7378114
[Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)]
Abstract
After the administration of 350 mg a retard preparation of theophylline-ethylenediamine (Aminophyllin retard) p.o. to 10 healthy test persons the absorption rate of theophylline amounted to an average of 84%, after which the absorption had not been fully completed in all persons after 10 h. Constant plasma levels appeared under the continuous administration of 350 mg of the retard preparation twice a day after 3-5 d; they were only a little above 5 mg/l, i.e. in the lower therapeutical range. After 15 d a clinically hardly significant increase in the theophylline clearance was found.
Similar articles
-
Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.Int J Clin Pharmacol Ther Toxicol. 1981 May;19(5):223-7. Int J Clin Pharmacol Ther Toxicol. 1981. PMID: 7251238
-
Absorption of sustained-release theophylline tablets.Int J Clin Pharmacol Ther Toxicol. 1983 Jul;21(7):359-62. Int J Clin Pharmacol Ther Toxicol. 1983. PMID: 6885207
-
Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.Int J Clin Pharmacol Ther Toxicol. 1983 Dec;21(12):624-30. Int J Clin Pharmacol Ther Toxicol. 1983. PMID: 6668100
-
[Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies].Fortschr Med. 1993 Oct 30;111(30):481-4. Fortschr Med. 1993. PMID: 8258429 Review. German.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.